Thomson ReutersOctober 24, 2013 16:32
By Ransdell Pierson
(Reuters) - Boston Scientific Corp <BSX.N>, which is in the midst of an attempted turnaround, reported weak sales of its heart stents and provided a disappointing fourth-quarter company sales forecast, sending its shares almost 7 percent lower on Thursday.
The medical device maker also caused market jitters by announcing that Jeffrey Capello, its chief financial officer since early 2010, would resign effective December 31. He will be replaced by Daniel Brennan, the company's corporate controller.